Abstract 12498: Antihypertensive Medication Use and Blood Pressure Control Among 384000 Chinese Adults: Pilot Results From the China PEACE Million Persons Project
Introduction: While high blood pressure (BP) is a leading risk factor for cardiovascular diseases, little is known about the current status of treatment and BP control in China. This study aims to characterize the patterns of antihypertensive medication use and BP control in a recent Chinese national screening project.
Methods: During the pilot phase of the China PEACE (Patient-Centered Evaluative Assessment of Cardiac Events) Million Persons Project, 384,234 adults aged 40-75 years were enrolled from the general population in four provinces in China between 2014-2015. We describe the prevalence, awareness, treatment, and control of hypertension in the study population, assess antihypertensive medication use, and characterize patients with uncontrolled hypertension using multivariate regression models. Hypertension was defined as BP ≥140/90mmHg, current antihypertensive medication use, or prior hypertension diagnosis. Awareness and control were defined as self-reported prior diagnosis and BP<140/90 mmHg, respectively, among those with hypertension.
Results: The prevalence of hypertension in middle-aged Chinese adults was 43.7%; the awareness, treatment, and control of hypertension were 38.6%, 28.2%, and 8.2% (Figure). Among patients receiving antihypertensive medication, 85.5% used one medication and 13.5% used two. Calcium channel blockers (CCB) were most commonly used (56.1%), followed by angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) (19.6%); CCB plus ACEI/ARB was the most commonly used combination therapy regimen (7.6%). Men, lower income, less education, and obesity were associated with uncontrolled hypertension (all p values<0.05).
Conclusions: Awareness, treatment, and control of hypertension were low in middle-aged Chinese adults, far lower than those in the United States. Improving BP control in China will likely require
improving diagnosis and more aggressive treatment.
Author Disclosures: Y. Lu: None. J. Lu: None. X. Cheng: None. L. Mu: None. X. Wang: None. X. Li: None. G. Linderman: None. H. Zhang: None. H. Zhao: None. E. Spatz: None. C. Wu: None. M. Su: None. J. Liu: None. J. Spertus: None. F. Masoudi: None. H. Krumholz: None. L. Jiang: None.
- © 2016 by American Heart Association, Inc.